ArticleEpilepsia open2025
Efficacy of phenobarbital is maintained after exposure to mild-to-moderate seizures in neonates.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Updated recommendations for the design of therapeutic trials for neonatal seizures.Pediatric research · 2026Review
- Rethinking the definition of neonatal status epilepticus.European journal of pediatrics · 2025Review
- Efficacy of phenobarbital is maintained after exposure to mild-to-moderate seizures in neonates.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To study the relationship between the delay in treatment and the efficacy of phenobarbital in neonates, we re-analyzed data from the NEOLEV2 study. Continuous video EEG (cEEG) from patients treated with phenobarbital was reviewed by neurophysiologists who marked each seizure. The time from seizure onset to phenobarbital, total seizure burden pre-phenobarbital, and maximum seizure density (summed seizure burden per hour) pre-phenobarbital were calculated and correlated with phenobarbital efficacy at 20 mg/kg and at 40 mg/kg. The time between seizure onset and phenobarbital treatment did not predict refractoriness to phenobarbital. However, the maximum seizure density per hour and total seizure burden before phenobarbital treatment were strongly correlated with efficacy. ROC curve analysis showed cut-offs of maximum seizure density pre-phenobarbital of 10 ½ min/h and total seizure burden pre-phenobarbital of 36 ¼ min had excellent discriminatory ability in separating patients in whom phenobarbital would be effective from patients in whom it would not be effective (AUC 0.84, p = 0.0002 and AUC 0.85, p = 0.0051). These data suggest that whereas neonates with high seizure density must be treated as an emergency, mild-to-moderate seizures remain responsive to phenobarbital if treated within a time frame of several hours. PLAIN LANGUAGE SUMMARY: Phenobarbital is very effective at stopping seizures in newborns. But if phenobarbital is given after many hours of seizures, it becomes less effective. We do not know how quickly this happens. Our study found that it does not happen over the short term (<4 h). It is more difficult to stop seizures that cumulatively last more than 10 min/h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.